Home › Compare › MLPKF vs ABBV
MLPKF yields 7.71% · ABBV yields 3.06%● Live data
📍 MLPKF pulled ahead of the other in Year 1
Combined, MLPKF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MLPKF + ABBV for your $10,000?
MLP SE, together with its subsidiaries, provides financial brokerage and consulting services to private, corporate, and institutional clients in Germany. The company's Financial Consulting segment offers consulting services for academics and other clients related to insurance, investments, occupational pension provision schemes, and loans and mortgages, as well as the brokering of contracts in financial services. Its Banking segment provides banking services, such as accounts, credit cards, loans, mortgages, and wealth management services. This segment also offers securities custody, commission, investment consulting, and insurance and investment brokerage services. The company's FERI segment provides wealth and investment consulting, as well as investment management and research services for institutional investors and high net-worth families and foundations. Its DOMCURA segment operates as an underwriting agency that designs, develops, and implements coverage concepts in the field of private and corporate non-life insurance products, as well as provides brokerage services. The company's Industrial Broker segment brokering of insurance policies for industrial and commercial clients, as well as consulting services and insurances. Its Holding and Others segment develops real estate properties. MLP SE was founded in 1971 and is headquartered in Wiesloch, Germany.
Full MLPKF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.